The new corona dynamic Trump was discharged from the hospital after three days of treatment, what exactly is he using the new coronavirus special effects drug?

Now is the National Day long holiday, at home for most of the year people have opened a "revenge outing", popular scenic spots across the country have a long-lost pattern of people and mountains, this scene will ythroid will either make many outbreaks are still serious or are in the second wave of the epidemic countries feel envious, thank the motherland's great anti-epidemic workers! I believe that we enjoy the hard-won long vacation at the same time, but also brushed a big news bar, U.S. President Trump also infected with the new crown virus! Although the White House has taken "strict" measures to protect the president from infection, including temperature measurements and virus testing by people entering the White House, it has not been spared.
that Mr. Trump's infection occurred at the justices' nomination ceremony, where seven people have been reported to have tested positive for the new coronavirus, a fear of a super-transmission in the White House.
Mr. Trump's diagnosis, the White House medical team developed treatments that included regeneron pharmaceutical company's experimental new coronavirus antibody cocktail therapy, zinc, vitamin D, and famotin.
Regeneron's antibody drug is still in the experimental stage and has not yet been approved for emergency use by the FDA, and the drug is based on a request for sympathetic medication (the first case of a new coronavirus infection using Redsyvir is also based on a compassionated drug request).
the White House medical team's use of experimental treatment options has its own considerations, and today we're looking at how the new coronavirus antibody therapy is produced.
is a positive antibody? The median antibody is a class of antibodies that prevent cells from being infected by pathogens (viruses or bacteria), and once the pathogen cannot continue to infect the cells, the progression of the disease is controlled, and the remaining pathogens are slowly removed by the body and eventually cured.
In the current situation, the antibody is also known as the new coronavirus "special effects drug", but because the antibody is a protein drug, its mass production, transportation and storage costs are relatively high, the price is more expensive.
antibodies are screened? At present, the meso-antibodies of the new coronavirus are screened out of the body of the newly crowned rehabilitation patients.
First isolates the patient's monocytes, then screens B cells that can bind to the new coronavirus S protein, sequences the DNA sequence of encoded antibodies, and then expresses the corresponding antibodies in a large number of cells through molecular biology, and finally detects their activity.
Intensive antibodies to the new coronavirus are primarily directed at the RBD region of the S protein (Receptor-binding domain, receptor binding domain), where the antibody binds to prevent the virus from binding to ACE2 on the surface of the human cell, thereby blocking the infection of the cell.
But not all of the immune antibodies are targeted at this domain, and a team of researchers at the Institute of Military Medicine, Chen Wei, found that an antibody 4A8 binds to the N-side domain of the S protein, which also has a strong meso-effect, indicating the diversity of the mechanisms of action of the nidal antibody.
antibody activity is detected? Strict positive activity detection requires the detection of live new coronavirus on cellular or animal models, but taking into account biosecurity risks and the urgent need for liposing antibodies, alternatives have been used in some early studies, such as Regeneron's antibody activity detection using VSV fake virus surface expression SARS-CoV2 S protein to simulate SARS-CoV2, showing better memorization effects on cell models and inhibiting concentrations as low as pimples (10-12).
Michael S. Diamond team at the University of Washington in Washington, D.C., has developed a way to evaluate and level antibody activity in mouse models.
the new coronavirus could not directly infect mice because of differences between ACE2 and human.
authors used adenovirus vectors to express the human ACE2 gene in mice, enabling them to successfully infect the new coronavirus and produce disease symptoms.
closer to human infection is the use of primate models, such as rhesus monkeys.
antibodies developed by the Institute of Microbiology of the Chinese Academy of Sciences showed good results on the model.
the current research progress of antibodies in the new coronavirus? There are several companies in the new crown and antibody is in clinical trials, such as Lilly, AstraZenecon, AbbVie, regenerative, etc. , the Chinese Academy of Sciences Institute of Microbiology and Junshi Bio jointly developed the new crown and antibody has also entered the first phase of clinical trials, Lilly and regeneratives are currently in a leading position, have entered phase III clinical trials.
But there is currently less clinical data on new crown neutralization antibodies, and on September 29th regenerative companies that provided Trump's drugs published the results of 275 non-hospitalized patients, and the company's antibody cocktail therapy improved symptoms and reduced viral load and better tolerance for patients with mild to medium-level disease.
new coronavirus is still raging around the world, the number of new cases remains high, vaccines and antibodies are important weapons to deal with viral infections, the world has invested huge resources in the development, hoping to control the virus as soon as possible, return to normal.
References: 1. Chi, X., et al., A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020. 369 (6504): p. 650-655.2. Hansen, J., et al., Studies in humanized mice and convalescent yield humans a SARS-CoV-2 antibody cocktail. Science, 2020. 369 (6506): p. 1010-1014.3. Hassan, A.O., et al., A SARS-CoV-2 Infect Model in MiceS Support by Neutralizing Antibodies. Cell, 2020. 182 (3): p. 744-753.e4.4. Shi, R., et al., A human neutral anti-izingbody targets the receptor-binding site of SARS-CoV-2. Nature, 2020. 584 (7819): p. 120-124. Cui Peng Source: Huashan Infection Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mes Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.